LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer [Yahoo! Finance]